Spiramid (AMI-193) je selektivni antagonist 5-HT2A, 5-HT1A, i D2 receptor. On ima neznatan afinitet za 5-HT2C receptor.[3][4][5]

Spiramid
(IUPAC) ime
8-[3-(4-Fluorofenoksi)propil]-1-fenil-1,3,8-triazaspiro[4,5]dekan-4-o
Klinički podaci
Identifikatori
CAS broj 510-74-7
ATC kod nije dodeljen
PubChem[1][2] 68186
UNII 471LF4O004 DaY
Hemijski podaci
Formula C22H27FN3O2 
Mol. masa 384,466 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

Reference uredi

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Czoty PW, Howell LL (October 2000). „Behavioral effects of AMI-193, a 5-HT(2A)- and dopamine D(2)-receptor antagonist, in the squirrel monkey”. Pharmacology, Biochemistry, and Behavior 67 (2): 257–64. DOI:10.1016/S0091-3057(00)00321-X. PMID 11124389. 
  4. Luparini MR, Garrone B, Pazzagli M, Pinza M, Pepeu G (November 2004). „A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone”. Progress in Neuro-psychopharmacology & Biological Psychiatry 28 (7): 1117–27. DOI:10.1016/j.pnpbp.2004.05.046. PMID 15610924. 
  5. Hamada K, Yoshida M, Isayama H, Yagi Y, Kanazashi S, Kashihara Y, Takeuchi K, Yamaguchi I (November 2007). „Possible involvement of endogenous 5-HT in aggravation of cerulein-induced acute pancreatitis in mice”. Journal of Pharmacological Sciences 105 (3): 240–50. DOI:10.1254/jphs.FP0071049. PMID 17965538. 

Spoljašnje veze uredi